Investors

Announcements

2022

Further re: Extension of Subscription Date

01 March 2021

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 6 January 2021 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 26 February 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company due to COVID-19 restraints experienced by ECP in completing their respective business matters, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 5 April 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented : " We are confident that the subscription will achieve a satisfactory outcome and both the Company and ECP are continuing to work closely together to build a valuable and significant relationship for the future of both parties. "

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

TruSpine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO

 

 

 

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

 

 

 

WH Ireland (Broker)

Tel: +44 ( 0)20 7220 1666

Adam Pollock

 

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]

    


Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2021

Further re: Extension of Subscription Date

01 March 2021

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 6 January 2021 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 26 February 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company due to COVID-19 restraints experienced by ECP in completing their respective business matters, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 5 April 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented : " We are confident that the subscription will achieve a satisfactory outcome and both the Company and ECP are continuing to work closely together to build a valuable and significant relationship for the future of both parties. "

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

TruSpine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO

 

 

 

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

 

 

 

WH Ireland (Broker)

Tel: +44 ( 0)20 7220 1666

Adam Pollock

 

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]

    


Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

2020

Further re: Extension of Subscription Date

01 March 2021

TruSpine Technologies plc (AQSE: TSP), the medical device company focused on the spinal (vertebral) stabilisation market, announces an update to the announcement released by the Company on 6 January 2021 in which it notified that the subscription funds of £250,000 ("Funds") from Evrensel Capital Partners Limited ("ECP") would be received by 26 February 2021 for the subscription for 694,444 new ordinary shares in the Company at a price of 36 pence per share.

The Company further advises that the Funds have not been received by the Company due to COVID-19 restraints experienced by ECP in completing their respective business matters, however the Company and ECP have reached a further agreement to extend the deadline for the subscription date to 5 April 2021.

The Company confirms that it is not reliant on these additional funds for its current working capital requirements.

Ian Roberts, CEO, commented : " We are confident that the subscription will achieve a satisfactory outcome and both the Company and ECP are continuing to work closely together to build a valuable and significant relationship for the future of both parties. "

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").

The Directors of the Company take responsibility for this announcement.

 

Enquiries:

TruSpine Technologies Plc

Tel: +44 (0)20 3638 5025

Ian Roberts, CEO

 

 

 

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

 

 

 

WH Ireland (Broker)

Tel: +44 ( 0)20 7220 1666

Adam Pollock

 

 

 

Walbrook PR (Financial PR & IR)

Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001

Anna Dunphy

[email protected]

    


Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.